title: [Vasopressin use in shock].
abstract: Arginine-vasopressin (VP), also known as the antidiuretic hormone, is essential for water homeostasis. Its synthesis and liberation depends on regulation of osmotic, hypovolemic, hormonal, and nonosmotic stimuli. It has been demonstrated that it is key for maintenance of cardiovascular homeostasis through vasomotor regulation, the determinant of systemic vascular resistance and mean arterial pressure, a process acting through V1 receptors. Shock state with refractory vasodilation seen in sepsis, systemic inflammatory response, hypovolemia, cardiac arrest, polytrauma, etc., is characterized by an initial phase of liberation and increased levels of VP followed by a second phase characterized by inappropriately low levels of this hormone that are associated with refractoriness to management with volume, inotropics, and vasopressors. It has been demonstrated in clinical and experimental studies that exogenous VP treatment under this condition increases systemic vascular resistance, perfusion pressure, and oxygen supply to peripheral tissues, which makes it possible to decrease and to suspend vasopressors and also to increase survival.
authors.affiliation: Hospital Central Sur de Alta Especialidad PEMEX Picacho, México, DF.
authors.forename: Raúl
authors.initials: R
authors.lastname: Carrillo-Esper
authors.forename: Jorge A
authors.initials: JA
authors.lastname: González-Salazar
authors.forename: Benjamín
authors.initials: B
authors.lastname: Calvo-Carrillo
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D012769:Shock / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000378:metabolism / Q000627:therapeutic use*; D014667:Vasopressins / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D014667:Vasopressins